Search Press releases Keywords From To 1 Sep 2014 New indication for VIMPAT® (lacosamide): UCB’s anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures Read More 1 Aug 2014 Transparency and Sharing: UCB Expands Access to Clinical Study Data Read More 30 Jul 2014 UCB Half Year Report 2014: UCB: solid performance and pipeline delivery Read More 23 Jul 2014 Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures Read More 3 Jul 2014 Acquisition of own shares Read More 3 Jul 2014 UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol) Read More Pagination First page Previous page Previous … Page 102 Page 103 Page 104 Page 105 Current page 106 Page 107 Page 108 Page 109 Page 110 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
